These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30652947)

  • 61. The clinical development of gamma-hydroxybutyrate (GHB).
    Wedin GP; Hornfeldt CS; Ylitalo LM
    Curr Drug Saf; 2006 Jan; 1(1):99-106. PubMed ID: 18690919
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical applications of sodium oxybate (GHB): from narcolepsy to alcohol withdrawal syndrome.
    Busardò FP; Kyriakou C; Napoletano S; Marinelli E; Zaami S
    Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4654-63. PubMed ID: 26698265
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Phenobarbital to manage severe gamma-hydroxybutyrate withdrawal: A case series.
    Freeman G; Siefried KJ; Roberts DM; Rodgers C; Nic Ionmhain U; Ramanathan J; Ezard N; Brett J
    Drug Alcohol Rev; 2023 Jan; 42(1):27-32. PubMed ID: 36269081
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Psychiatric comorbidity, psychological distress, and quality of life in gamma-hydroxybutyrate-dependent patients.
    Kamal RM; Dijkstra BA; de Weert-van Oene GH; van Duren JA; de Jong CA
    J Addict Dis; 2017; 36(1):72-79. PubMed ID: 27449738
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Gamma-hydroxybutyrate (GHB): a newer drug of abuse.
    O'Connell T; Kaye L; Plosay JJ
    Am Fam Physician; 2000 Dec; 62(11):2478-83. PubMed ID: 11130233
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Depression Following γ-Hydroxybutyrate Withdrawal: A Case Report.
    Domínguez I; Bruguera P; Balcells-Oliveró M; Batalla A
    J Clin Psychopharmacol; 2015 Oct; 35(5):618-9. PubMed ID: 26284931
    [No Abstract]   [Full Text] [Related]  

  • 67. Gamma-hydroxybutyrate (GHB): a scoping review of pharmacology, toxicology, motives for use, and user groups.
    Brennan R; Van Hout MC
    J Psychoactive Drugs; 2014; 46(3):243-51. PubMed ID: 25052883
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Psychosis in the context of sodium oxybate therapy.
    Langford J; Gross WL
    J Clin Sleep Med; 2011 Dec; 7(6):665-6. PubMed ID: 22171207
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The behavioural profile of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol in humans.
    Bosch OG; Seifritz E
    Brain Res Bull; 2016 Sep; 126(Pt 1):47-60. PubMed ID: 26855327
    [TBL] [Abstract][Full Text] [Related]  

  • 70. GHB concentration in a related post-mortem case.
    Mortali C; Berretta P
    Clin Ter; 2020; 171(3):e235-e236. PubMed ID: 32323711
    [TBL] [Abstract][Full Text] [Related]  

  • 71. GHB-induced delirium: a case report and review of the literature of gamma hydroxybutyric acid.
    Hernandez M; McDaniel CH; Costanza CD; Hernandez OJ
    Am J Drug Alcohol Abuse; 1998 Feb; 24(1):179-83. PubMed ID: 9513637
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse.
    Carter LP; Pardi D; Gorsline J; Griffiths RR
    Drug Alcohol Depend; 2009 Sep; 104(1-2):1-10. PubMed ID: 19493637
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Trends in gamma-hydroxybutyrate-related harms based on ambulance attendances from 2012 to 2018 in Victoria, Australia.
    Arunogiri S; Moayeri F; Crossin R; Killian JJ; Smith K; Scott D; Lubman DI
    Addiction; 2020 Mar; 115(3):473-479. PubMed ID: 31618793
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The assessment and management of gamma hydroxybutyrate use in general practice.
    Phan V; Arunogiri S; Lubman DI
    Aust J Gen Pract; 2020; 49(1-2):73-78. PubMed ID: 32008260
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical relevance of ethanol coingestion in patients with GHB/GBL intoxication.
    Galicia M; Dargan PI; Dines AM; Yates C; Heyerdahl F; Hovda KE; Giraudon I; ; Wood DM; Miró Ò;
    Toxicol Lett; 2019 Oct; 314():37-42. PubMed ID: 31301370
    [TBL] [Abstract][Full Text] [Related]  

  • 76. High-risk behaviors and hospitalizations among gamma hydroxybutyrate (GHB) users.
    Kim SY; Anderson IB; Dyer JE; Barker JC; Blanc PD
    Am J Drug Alcohol Abuse; 2007; 33(3):429-38. PubMed ID: 17613970
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Liquid ecstasy in general psychiatry: a case series].
    Freudenmann RW; Baumgarten E; Hawlik AE; Gahr M; Schönfeldt-Lecuona CJ
    Fortschr Neurol Psychiatr; 2013 Feb; 81(2):88-94. PubMed ID: 23412960
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Commentary on Bell & Collins (2011): Out-patient management of gamma-hydroxy butyric acid (GHB) withdrawal - an alternative strategy for the future?
    Zepf FD
    Addiction; 2011 Feb; 106(2):448. PubMed ID: 21208322
    [No Abstract]   [Full Text] [Related]  

  • 79. Successful treatment of severe, treatment resistant GHB withdrawal through thiopental-coma.
    Vos CF; Pop-Purceleanu M; van den Berg MJW; Schellekens AFA
    Subst Abus; 2021; 42(1):33-38. PubMed ID: 33044905
    [TBL] [Abstract][Full Text] [Related]  

  • 80. γ Hydroxybutyrate use: exploring the influence of outcome expectancies through memory modeling.
    Brown PC; Alfonso J; Dunn ME
    Am J Addict; 2011; 20(2):127-36. PubMed ID: 21314755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.